Seeking to provide its pricey gene therapy to patients in countries where the drug is not yet approved, Novartis (NVS) has taken the unusual step of creating a lottery, a move that drew criticism from patient groups over concerns the approach would unfairly forsake some babies.

At issue is access to Zolgensma, which costs $2.1 million per patient and is used to combat spinal muscular atrophy, a rare inherited disease that afflicts children up to 2 years old and often leads to death. The treatment is available in the U.S., but not yet in Europe or Japan, where approval is expected next year. Meanwhile, parents have been clamoring for the medicine.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy